Acta pharmaceutica Sinica. B · 2026
Metrnl in mitigating radiation enteritis via label-retaining cells protection by modulating the c-KIT-WNT pathway.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Sailong, Chen Simin, Guo Bingjie, Ling Qisheng, Wang Shuling, Miao Zhuwei, Wang Zhi, Wei Yuchen, Zheng Sili, Li Zhiyong, Feng An-Qiang, Qian Feng-Hua, Miao Chao-Yu
Аннотация
Currently, there exists no definitive standardized therapy for radiation enteritis. This study unveils Metrnl as a pivotal regulator of intestinal radioprotection through multi-dimensional single-cell profiling and mechanistic dissection. We first demonstrate that radiation dynamically reprograms Metrnl expression in a time-dependent manner, revealing its role as a radiation-responsive mediator. Crucially, Metrnl confers potent protection against radiation-induced intestinal injury through double mechanisms; Metrnl safeguards label-retaining cells (LRCs) rather than conventional Lgr5+ intestinal stem cells, and activates a novel c-KIT-WNT signaling axis via ERK/GSK3β-mediated pathway crosstalk, both revitalizing intestinal epithelial regeneration. Therapeutically, recombinant Metrnl emerges as a potential biotherapeutic, effectively attenuating radiation enteritis. These findings establish Metrnl as a key mediator bridging radiation biology and regenerative medicine, offering a transformative potential for radiation injury management.